| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
This report analyzes the worldwide markets for Automated and Rapid
Microbiological Tests in Millions of US$. The Major End-Use Segments Analyzed
are Clinical Applications (Automated Identification & Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal
Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid
Microbiological Tests), and Non-Clinical Applications. The report provides
separate comprehensive analytics for the US, Europe, and Rest of World. Annual
forecasts are provided for each region for the period of 2000 through 2015.
The report profiles 128 companies including many key and niche players
worldwide such as Abbott Laboratories, Abbott Diagnostics, Becton Dickinson
and Company, bioMerieux, bioMerieux, Inc., Bio-Rad Laboratories, Cellabs Pty
Ltd, Celsis International Plc., Coris BioConcept, F. Hoffmann-La Roche Ltd.,
Gen-Probe Incorporated, Genzyme Diagnostics, Inverness Medical Innovations,
Inc., Unipath Limited, MedMira Inc., Meridian Biosciences, Inc., Orasure
Technologies, Inc., Orion Diagnostica Oy, Quidel Corporation, Siemens Medical
Solutions Diagnostics, Thermo Fisher Scientific, Inc., Remel, Inc., and Oxoid
Limited. Market data and analytics are derived from primary and secondary
research. Company profiles are mostly extracted from URL research and reported
select online sources.
TABLE OF CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- Automated and Rapid Microbiological Tests: A Definition
- Clinical Applications
- Automated Identification and Susceptibility Systems
- Automated Blood Culture Systems
- Automated Tuberculosis Systems
- Streptococcal Infection Rapid Tests
- GC/Chlamydia Rapid Tests
- Other Automated & Rapid Microbiological Tests
- Non-Clinical Applications
II. EXECUTIVE SUMMARY
1. Industry Overview
- Outlook
- Evolutionary Battle Against the Bugs Drives the Future of the Market ...
- Automated Microbiological Tests: A Pesky Gray Area in the Clinical
Diagnostics Market
- Traditional Rapid Microbiological Tests Destined to Go Out With the Old
- A Current & Future Analysis
- Segmental Perspective
- Clinical Applications
- Non-Clinical Applications
- Macro: The Big Picture
- Deciding the Market's Future...
- A Holistic Peek into a Few Noteworthy Trends
- Biotechnology & Rapid Microbial Tests
- Automated & Rapid Microbiological Tests: "Current Market
Stance"
- A Business Case for Automated & Rapid Microbiological Testing
- Near Patient Testing: An Offshoot of Rapid Microbiological Tests
- Pros & Cons of Near Patient Testing
- Role of Near Patient Testing in Reducing Antibiotic Resistance in Humans
- The Pre/Post Microbial Rapid Testing Era: A Review
- Market Structure
- Competitive Setup of the Diverse Automated & Rapid Microbiology
Products Market
- Historic Data
- Table 1: Leading Players in World Market for IVD Automated Microbiology
Systems (2000) - Percentage Breakdown of Value Sales by Company forbioMerieux,
Dade Behring, Becton Dickinson,Organon Teknika, and Others
(includescorresponding Graph/Chart)
2. Trends & Issues
- Advancements in Molecular Diagnostics - A Boon or a Threat
- Antibiotic Resistant Bacteria Throws the Spotlight On Microbial Testing
- Instant Detection of Pathogens - A New Epoch in the Fight for Survival
- Lower Cost Rapid Tests Built on Multiple Sampling Modalities - Gaining
Momentum
- "Time Constraints?" - Rapid Tests to the Rescue
- Rapid HIV Tests: A New Age Diagnostic Weapon Against the Killer Disease
- Accuracy/Reliability of Home HIV Testing: A Bone of Contention
- Development of Near Patient Test Kits: A Market Driven Phenomenon
- Near Patient Test Kits: A Rumination of Possibilities
- Automated Blood Culture Systems: A Winning Edge in the Fight Against
Bacteremia
- Leading Food Processors Resort to Rapid Microbiological Testing
- Impact of Food Scares on Rapid Microbiological Tests Market
- Demand for Microbiological Tests & Level of QC in the Food Industry
- Rapid Tests Creating Brighter Avenues in Food Microbiology Testing Market
- Dire Need to Nip Operating Costs Throws the Spotlight on Rapid Tests
- Key Advantages/Benefits of Rapid Microbiological Tests on Food
- Food Packages of the Future Ingrained with Microbial Alert Systems
- Technology Innovations in Rapid Food Microbial Testing
- Obtaining Regulatory Approval - A Major Non-Technical Hindrance
3. Factors Influencing the Market
- Continuing Biological Warfare with Pathogens Sparks Market Growth ...
- Innovative Products - A Key Growth Strategy
- Other Market Drivers in a Capsule
- Low Turnaround Times Skyrocket Demand
- Greater Patient Awareness
- Rising Incidence of STDs Kindles Universal Market Acceptance
- Ultra-Rapid HIV-Screening Tests- A Strong Fight against HIV-Epidemic
- Validation of Rapid Microbiological Tests: An Imperative Prerequisite
- Non-Conformance to Testing Requirements: A Weighty Concern
- Influenza - Boosting Rapid Test Prospects
4. Product/Technology Overview
- Automated & Rapid Microbiological Tests: A Definition
- Benefits of Automated & Rapid Microbiological Tests
- Classification of Rapid Microbiological Test Methods
- How Does a Rapid Test Work?
- Sample Preparation - A Key Procedure
- Automated Identification and Susceptibility Systems
- Automated Blood Culture Systems
- Automated Tuberculosis Systems
- Microminiaturization of Diagnostic Tests: How Is It Effected?
- Advantages of Microminiaturisation:
- Acid-Fast Microscopy - The Forerunner of Rapid Tests
- Gram's Stain: A Time-Honored & Rapid Method to Detect Pathogens in
Blood
- Enabling Technologies of Automated & Rapid Microbiological Tests
- Growth-based Technologies
- Viability-based Technologies
- Cellular-Component or Artifact-based Technologies
- Genomics/ Proteomics
- Microarrays/ Microfluidics
- DNA Microchips/Probes
- Polymerase Chain Reaction (PCR)
- Immunoassay
- Immunoassay Escalates into Diverse Fields of Diagnostic Testing
- Nucleic Acid Testing (NAT)
- Nucleic Acid Probes
- Signal-Amplified Tests
- Nucleic Acid Amplification Tests
- Traditional Methods with Computer-Aided Imaging
- Combination Methods
5. End-Use Application Analysis
- Applications in Clinical Investigations
- STD Rapid Tests
- GC/Chlamydia Rapid Tests
- HIV Rapid Tests
- HIV Facts & Figures
- Advantages of Rapid HIV Testing
- Disadvantages of Rapid HIV Testing
- Syphilis Rapid Tests
- Respiratory Rapid Tests
- RSV/ Influenza Rapid Tests
- Tuberculosis Rapid Tests
- Group A beta Hemolytic Streptococcus Rapid Tests
- Mononucleosis Rapid Tests
- Streptococcus Rapid Tests
- Streptococcus A Rapid Tests
- Streptococcus B Rapid Tests
- Gastrointestinal Rapid Tests
- Giardia Lamblia Rapid Tests
- H. Pylori Rapid Tests
- Cryptosporidium Rapid Tests
- C. Difficile Rapid Tests
- Applications in Non-Clinical Investigations
- Food/Water Safety Tests
- Food Safety Testing: A Lucrative Application Area
- Rapid Microbiological Methods in Pharmaceutical Sector
- Limitations of RMMs
- Advantages of RMMs
- Applications in Pharmaceutical Sector
- Environmental Tests
- Other Miscellaneous Applications
6. Product Innovations/Introductions
- Meridian Bioscience Rolls Out Two New Rapid Tests for Detecting
Epstein-Barr Virus
- Oxoid Introduces Staph Plus System for Identifying Staphylococcal Species
- Siemens Healthcare Diagnostics Launches MicroScan® WalkAway® plus
Diagnostic Microbiology Systems
- Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelect™ test,
in US
- bioMerieux Introduces VIDAS®, an automated Clostridium difficile A
& B Toxins Detection Test
- Oxoid Launches Remel Wellcolex® Colour Tests for Testing Shigella, E.
coli O157 and Salmonella
- Siemens Healthcare Diagnostics Obtains Health Canada Approval for its
VERSANT 440 Molecular System
- Oxoid Unveils Remel Xpect™ Clostridium Difficile Toxin A/B Test
- Neogen Introduces Soleris System
- ATCC Introduces Authenticult™ Quality Control Microbiological
Testing Tool
- Bio-Rad Introduces New EBV Kits
- Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test
- Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test
- FDA Clears Usage of TIGRIS® System for Testing WNV in Donated Blood
- FDA Approves ImmunoCard STAT!® EHEC for Detecting E. coli Infection
- bioMerieux Introduces TEMPO® Quality Indicator Testing System
- Biotrace Introduces Tecra Unique Campylobacter Rapid Test
- bioMerieux Introduces TEMPO® EB test for Enterobacteriaceae
- Roche Unveils Elecsys TORCH Assays
- Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan
- bioMerieux Develops Advanced Colorimetry™ NH Card
- Roche Introduces Rapid LightCycler SeptiFast Sepsis Test across EU
- Oxoid Launches New Rapid Test for Salmonella Detection in Food Products
- Oxoid Unveils New Contact Plate Design
- FDA Approves Fluconazole Susceptibility Tests from BioMerieux
- Polysciences Unveils New Microbiological & Bacterial Detection
Applications
- Researchers Develop New Rapid MODS Test for TB Detection
- Dade Behring Unveils Automated Quadriga BeFree System
- FDA Approves Abbott PRISM® HBsAg Assay
- Bayer's EHIV Test Receives FDA Clearance
- Gen-Probe Obtains FDA Approval to Use Aptima Test on Additional Specimens
- Roche Diagnostics' cobas TaqScreen MPX Test Receives CE Mark Approval
- Cepheid Introduces Rapid Xpert® MRSA Test in Europe
- Bio-Rad Widens Culture Media with Addition of RAPID'Salmonella
- Chemogen Develops New Tuberculosis Rapid Test
- bioMerieux Rolls Out VIDAS® LDUO Test
- Zonda Develops New Rapid Test for Chlamydia
- MedMira Launches MiraCare Rapid HIV Test
- STMicroelectronics and Mobidiag Unveil Lab-On-Chip
- Vermicon Launches ScanVIT-Legionella Rapid Test Kit
- New Line of Rapid Microbial Detection Systems from Centrus
- OraSure Rolls Out OraQuick ADVANCE
- Abbott Unveils Automated HCV Test
- ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and Respiratory
Pathogens
- Biophage Pharma Offers Service for Microbiological Testing
- bioMerieux Releases New Rapid Test for Nosocomial Infections
- bioMerieux Widens Product Portfolio with Addition of TEMPO® System
- Celsis Introduces CellScan Innovate Rapid Screening System
- Millipore Rolls Out Rapid Microbiology Detection System
- Calypte Biomedical Develops Oral Fluid Rapid Test for HIV- 1/2
- BioMerieux Unveils VITEK® 2 Compact
- Bio-Rad Unveils New Test Kits and Comprehensive Automated Systems
7. Recent Industry Activity
- Becton, Dickinson Establishes New Rapid Diagnostic Products Manufacturing
Facility in China
- Quidel Corporation Obtains CLIA Waiver from US FDA for its QuickVue®
RSV Test
- Siemens Obtains US FDA Approval for its VERSANT™ 440 Molecular System
- bioMerieux to Market Wescor's Customized Slide Stainer Instruments under
bioMerieux Brand
- Schering-Plough and OraSure Ink Collaboration Agreement for Developing
Rapid Oral HCV Test
- Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV-II Blood
Screening Test
- Quidel and bioMerieux Form a Long-term Alliance in Rapid Diagnostic Tests
- BD Diagnostics Obtains US FDA Approval BD GeneOhm™ StaphSR assay
- Meridian Bioscience Obtains US FDA Approval for Two New Rapid Tests
- Siemens AG Acquires Dade Behring
- Thermo Fisher Scientific Teams Up with KBA for Expanding its Microbiology
Business Division in Lenexa
- OraSure and SCMS Enter into an Agreement for Supplying OraQuick® HIV
Test to PEPFAR Countries
- Abbott Obtains US FDA Approval for its Fully Automated PRISM® HCV Test
- Gen-Probe Obtains US FDA Approval for its PROCLEIX® TIGRIS® System
for Testing Donated Blood
- AdvanDx Ropes In bioMerieux for Distributing its Rapid Diagnostic Tests in
US
- 3M and Gen-Probe Join Hands to Develop Rapid Molecular Tests For Detecting
HAIs
- Gen-Probe's PROCLEIX® TIGRIS® System Obtains US FDA Approval for
Screening Donated Blood for West Nile Virus
- 3M Acquires Acolyte Biomedica
- Formation of Siemens Medical Solutions Diagnostics
- bioMerieux Bags Contract to Provide VITEK® 2 System for Scottish NHS
Labs
- bioMerieux Licenses NorChip's HPV Test Technology for Cervical Cancer
- bioMerieux in Strategic Agreement with Cepheid for Sepsis Assays
- 3M Health Care Creates New Medical Diagnostics Unit
- Schering-Plough & OraSure to Develop Rapid Oral HCV Test
- 3M Acquires Biotrace International
- Siemens Acquires DPC
- Oxoid Acquires Microbiology Business Activities of Dako
- Inverness Acquires IDT and Thermo BioStar
- BMD in Agreement with MND for Research on Diagnostic Tests
- Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus Detection Test
- Dutch Government Grants ?7.9 Million to FIND
- FIND and Hain to Develop Rapid Test for MDR and XDR TB
- 3M & Gen-Probe Ally for Developing Rapid Molecular Tests for Food
Safety
- Continuing Biological Warfare with Pathogens Sparks Market Growth ...
- Innovative Products - A Key Growth Strategy
- Other Market Drivers in a Capsule
- Low Turnaround Times Skyrocket Demand
- Greater Patient Awareness
- Rising Incidence of STDs Kindles Universal Market Acceptance
- Ultra-Rapid HIV-Screening Tests- A Strong Fight against HIV-Epidemic
- Validation of Rapid Microbiological Tests: An Imperative Prerequisite
- Non-Conformance to Testing Requirements: A Weighty Concern
- Influenza - Boosting Rapid Test Prospects
4. Product/Technology Overview
- Automated & Rapid Microbiological Tests: A Definition
- Benefits of Automated & Rapid Microbiological Tests
- Classification of Rapid Microbiological Test Methods
- How Does a Rapid Test Work?
- Sample Preparation - A Key Procedure
- Automated Identification and Susceptibility Systems
- Automated Blood Culture Systems
- Automated Tuberculosis Systems
- Microminiaturization of Diagnostic Tests: How Is It Effected?
- Advantages of Microminiaturisation:
- Acid-Fast Microscopy - The Forerunner of Rapid Tests
- Gram's Stain: A Time-Honored & Rapid Method to Detect Pathogens in
Blood
- Enabling Technologies of Automated & Rapid Microbiological Tests
- Growth-based Technologies
- Viability-based Technologies
- Cellular-Component or Artifact-based Technologies
- Genomics/ Proteomics
- Microarrays/ Microfluidics
- DNA Microchips/Probes
- Polymerase Chain Reaction (PCR)
- Immunoassay
- Immunoassay Escalates into Diverse Fields of Diagnostic Testing
- Nucleic Acid Testing (NAT)
- Nucleic Acid Probes
- Signal-Amplified Tests
- Nucleic Acid Amplification Tests
- Traditional Methods with Computer-Aided Imaging
- Combination Methods
5. End-Use Application Analysis
- Applications in Clinical Investigations
- STD Rapid Tests
- GC/Chlamydia Rapid Tests
- HIV Rapid Tests
- HIV Facts & Figures
- Advantages of Rapid HIV Testing
- Disadvantages of Rapid HIV Testing
- Syphilis Rapid Tests
- Respiratory Rapid Tests
- RSV/ Influenza Rapid Tests
- Tuberculosis Rapid Tests
- Group A beta Hemolytic Streptococcus Rapid Tests
- Mononucleosis Rapid Tests
- Streptococcus Rapid Tests
- Streptococcus A Rapid Tests
- Streptococcus B Rapid Tests
- Gastrointestinal Rapid Tests
- Giardia Lamblia Rapid Tests
- H. Pylori Rapid Tests
- Cryptosporidium Rapid Tests
- C. Difficile Rapid Tests
- Applications in Non-Clinical Investigations
- Food/Water Safety Tests
- Food Safety Testing: A Lucrative Application Area
- Rapid Microbiological Methods in Pharmaceutical Sector
- Limitations of RMMs
- Advantages of RMMs
- Applications in Pharmaceutical Sector
- Environmental Tests
- Other Miscellaneous Applications
6. Product Innovations/Introductions
- Meridian Bioscience Rolls Out Two New Rapid Tests for Detecting
Epstein-Barr Virus
- Oxoid Introduces Staph Plus System for Identifying Staphylococcal Species
- Siemens Healthcare Diagnostics Launches MicroScan® WalkAway® plus
Diagnostic Microbiology Systems
- Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelect™ test,
in US
- bioMerieux Introduces VIDAS®, an automated Clostridium difficile A
& B Toxins Detection Test
- Oxoid Launches Remel Wellcolex® Colour Tests for Testing Shigella, E.
coli O157 and Salmonella
- Siemens Healthcare Diagnostics Obtains Health Canada Approval for its
VERSANT 440 Molecular System
- Oxoid Unveils Remel Xpect™ Clostridium Difficile Toxin A/B Test
- Neogen Introduces Soleris System
- ATCC Introduces Authenticult™ Quality Control Microbiological
Testing Tool
- Bio-Rad Introduces New EBV Kits
- Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test
- Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test
- FDA Clears Usage of TIGRIS® System for Testing WNV in Donated Blood
- FDA Approves ImmunoCard STAT!® EHEC for Detecting E. coli Infection
- bioMerieux Introduces TEMPO® Quality Indicator Testing System
- Biotrace Introduces Tecra Unique Campylobacter Rapid Test
- bioMerieux Introduces TEMPO® EB test for Enterobacteriaceae
- Roche Unveils Elecsys TORCH Assays
- Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan
- bioMerieux Develops Advanced Colorimetry™ NH Card
- Roche Introduces Rapid LightCycler SeptiFast Sepsis Test across EU
- Oxoid Launches New Rapid Test for Salmonella Detection in Food Products
- Oxoid Unveils New Contact Plate Design
- FDA Approves Fluconazole Susceptibility Tests from BioMerieux
- Polysciences Unveils New Microbiological & Bacterial Detection
Applications
- Researchers Develop New Rapid MODS Test for TB Detection
- Dade Behring Unveils Automated Quadriga BeFree System
- FDA Approves Abbott PRISM® HBsAg Assay
- Bayer's EHIV Test Receives FDA Clearance
- Gen-Probe Obtains FDA Approval to Use Aptima Test on Additional Specimens
- Roche Diagnostics' cobas TaqScreen MPX Test Receives CE Mark Approval
- Cepheid Introduces Rapid Xpert® MRSA Test in Europe
- Bio-Rad Widens Culture Media with Addition of RAPID'Salmonella
- Chemogen Develops New Tuberculosis Rapid Test
- bioMerieux Rolls Out VIDAS® LDUO Test
- Zonda Develops New Rapid Test for Chlamydia
- MedMira Launches MiraCare Rapid HIV Test
- STMicroelectronics and Mobidiag Unveil Lab-On-Chip
- Vermicon Launches ScanVIT-Legionella Rapid Test Kit
- New Line of Rapid Microbial Detection Systems from Centrus
- OraSure Rolls Out OraQuick ADVANCE
- Abbott Unveils Automated HCV Test
- ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and Respiratory
Pathogens
- Biophage Pharma Offers Service for Microbiological Testing
- bioMerieux Releases New Rapid Test for Nosocomial Infections
- bioMerieux Widens Product Portfolio with Addition of TEMPO® System
- Celsis Introduces CellScan Innovate Rapid Screening System
- Millipore Rolls Out Rapid Microbiology Detection System
- Calypte Biomedical Develops Oral Fluid Rapid Test for HIV- 1/2
- BioMerieux Unveils VITEK® 2 Compact
- Bio-Rad Unveils New Test Kits and Comprehensive Automated Systems
7. Recent Industry Activity
- Becton, Dickinson Establishes New Rapid Diagnostic Products Manufacturing
Facility in China
- Quidel Corporation Obtains CLIA Waiver from US FDA for its QuickVue®
RSV Test
- Siemens Obtains US FDA Approval for its VERSANT™ 440 Molecular System
- bioMerieux to Market Wescor's Customized Slide Stainer Instruments under
bioMerieux Brand
- Schering-Plough and OraSure Ink Collaboration Agreement for Developing
Rapid Oral HCV Test
- Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV-II Blood
Screening Test
- Quidel and bioMerieux Form a Long-term Alliance in Rapid Diagnostic Tests
- BD Diagnostics Obtains US FDA Approval BD GeneOhm™ StaphSR assay
- Meridian Bioscience Obtains US FDA Approval for Two New Rapid Tests
- Siemens AG Acquires Dade Behring
- Thermo Fisher Scientific Teams Up with KBA for Expanding its Microbiology
Business Division in Lenexa
- OraSure and SCMS Enter into an Agreement for Supplying OraQuick® HIV
Test to PEPFAR Countries
- Abbott Obtains US FDA Approval for its Fully Automated PRISM® HCV Test
- Gen-Probe Obtains US FDA Approval for its PROCLEIX® TIGRIS® System
for Testing Donated Blood
- AdvanDx Ropes In bioMerieux for Distributing its Rapid Diagnostic Tests in
US
- 3M and Gen-Probe Join Hands to Develop Rapid Molecular Tests For Detecting
HAIs
- Gen-Probe's PROCLEIX® TIGRIS® System Obtains US FDA Approval for
Screening Donated Blood for West Nile Virus
- 3M Acquires Acolyte Biomedica
- Formation of Siemens Medical Solutions Diagnostics
- bioMerieux Bags Contract to Provide VITEK® 2 System for Scottish NHS
Labs
- bioMerieux Licenses NorChip's HPV Test Technology for Cervical Cancer
- bioMerieux in Strategic Agreement with Cepheid for Sepsis Assays
- 3M Health Care Creates New Medical Diagnostics Unit
- Schering-Plough & OraSure to Develop Rapid Oral HCV Test
- 3M Acquires Biotrace International
- Siemens Acquires DPC
- Oxoid Acquires Microbiology Business Activities of Dako
- Inverness Acquires IDT and Thermo BioStar
- BMD in Agreement with MND for Research on Diagnostic Tests
- Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus Detection Test
- Dutch Government Grants ?7.9 Million to FIND
- FIND and Hain to Develop Rapid Test for MDR and XDR TB
- 3M & Gen-Probe Ally for Developing Rapid Molecular Tests for Food
Safety
- Bio View Inks Three-Year Distribution Agreement with Abbott Molecular
- Bodycote Acquires Foodscan Laboratories
- Cepheid Bags STTR Funding for Development of Rapid TB Test
- Abbott and Verax in Distribution Agreement for Verax Platelet PGD® Test
- BSL Supplies ABBOTT PRISM® System to Blood Donor Testing Centers
- Abbott & ARC in Agreement for Automated Blood Screening Tests
- BD to Set Up Production Facility for Rapid Diagnostic Products in China
- BD Diagnostics Delivers STI Testing Products to BioReference
- Meridian Licenses LAMP Diagnostic Test Technology from Eiken
- OraSure Inks Multi-Year Purchase Contract with New York City
- Abbott Inks Single-Source Agreement with Novation for HIV Test
- Neogen Takes Over Centrus International
- Becton, Dickinson and Company Acquires GeneOhm Sciences
- Inverness Medical Innovations Makes a Synergetic Purchase of ACON
Laboratories
- Quest Diagnostics Strikes Deal with BD Diagnostics
- Novation Inks Pact with Abbott for Rapid HIV-1/2 Antibody Test
- TREK Diagnostic and Novation Inks Agreement
- Clinton Foundation Inks Agreement with Four Companies to Cut Prices
- Chembio Obtains FDA Approval for HIV 1/2 Stat-Pak and Sure Check HIV 1/2
Rapid Test PMAs
- Roche's LightCycler SeptiFast Test Attains CE Mark
- Zonda Expands Distribution of Products in Europe
- OraSure Wins Rapid HIV Tests Order
- MedMira Secures Orders for Rapid HIV Tests
- Cepheid Collaborates with Foundation for Innovative Diagnostics
- Chembio Obtains Clearance for Rapid HIV Tests in Kenya
- Genesis Bioventures Bags US Patent for Rapid Prion- Detection Assay
- MedMira Obtains CE Mark for MiraCare
- Setema to Distribute Chembio's Rapid HIV Tests in Ethiopia
- Clinton Foundation HIV/AIDS Initiative Selects Chembio to Provide Rapid
HIV Tests
- Quidel Acquires immunochemical Fecal Occult Blood Test
- Xact Aid Snaps Up STD Alert
- Grant Life Sciences Acquires Rapid Tests from AccuDx
- Millipore Ties Up with Gen-Probe
- Foundation for Innovative New Diagnostics forms Collaboration with Eiken
Chemical
- WayPoint and Global Rapid Diagnostic Leader Enter into an Agreement
- Akers Biosciences Enters into a Distribution Agreement with Alco Industries
- Celsis and BioVentures Enter into Licensing Agreement
- Thermo Electron Inks Pact with Genomic Profiling Systems
- Abbott and OraSure Enters into Agreement for OraQuick ADVANCE Rapid
HIV-1/2 Test
- bioMerieux Signs Agreement with Novel Diagnostics
- Dade Behring Bags FDA Approval for Antimicrobial Susceptibility Test Panels
- OraSure Bags HCV Patent License from Chiron and Ortho- Clinical Diagnostics
- BD Diagnostics Receives FDA Approval for BD Directigen™ EZ Flu A+B
Test
- BD Diagnostics Bags FDA Clearance for BBL™ CHROMagar™ MRSA
Product
- MedMira Obtains Rights to Market Rapid HIV Tests in Guizhou Province, China
- Gen-Probe Obtains FDA Clearance for PROCLEIX® West Nile Virus Assay
- Medical Services International Secures Clearance for Rapid Test Kits
- Medical Services International Receives Exclusive Marketing Rights for TB
Test Kit
- Adaltis Receives Orders for HIV Rapid Tests from China
- MedCap Bags Exclusive Distribution Rights for Syphilis Rapid Test
- Genomic Profiling Systems Obtains NIAID Funds to Develop Testing Platform
- Gen-Probe Obtains US Patent for Automated Process for Nucleic Acid Testing
- Bio-Rad Receives Approval for HIV-1/HIV-2 Rapid Test
- Cambrex Makes a Synergetic Purchase of Genolife
- Cambrex Bioproducts Acquires Worldwide License from Epoch Biosciences
- Cambrex Forges Licensing Agreement with John Hopkins University
- Calypte Biomedical and Adaltis Enters into an Agreement
- Calypte Biomedical Signs MoU with Pacific Biotech
- GlaxoSmithKline Process Employing Pall Rapid Test Receives FDA Approval
- Binax Receives FDA Approval for NOW Influenza A & B Rapid Test
- Spectral Diagnostics and IDx Inc. Announce US$12 Million R&D Project
- Genome Therapeutics Transfers Streptococcus Pneumoniae Patent to Aventis
- Abbott Inks an Agreement with BioGenex Laboratories
- Bio-Rad and Enzon Announce Marketing Agreement
- bioMerieux and Omnimed Join Forces to Fight Against AIDS
8. Focus on Select Global Players
- Abbott Laboratories (USA)
- Abbott Diagnostics (USA)
- Becton Dickinson and Company (USA)
- bioMerieux (France)
- bioMerieux, Inc. (USA)
- Bio-Rad Laboratories (USA)
- Cellabs Pty Ltd (Australia)
- Celsis International Plc (UK)
- Coris BioConcept (Belgium)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Gen-Probe Incorporated (USA)
- Genzyme Diagnostics (USA)
- Inverness Medical Innovations, Inc. (USA)
- Unipath Limited (UK)
- MedMira Inc. (Canada)
- Meridian Biosciences, Inc. (USA)
- Orasure Technologies, Inc. (USA)
- Orion Diagnostica Oy (Finland)
- Quidel Corporation (USA)
- Siemens Medical Solutions Diagnostics (USA)
- Thermo Fisher Scientific, Inc. (USA)
- Remel, Inc. (USA)
- Oxoid Limited (UK)
9. Global Market Perspective
- Table 2: World Recent Past, Current & Future Market Analysis for
Automated and Rapid Microbiological Tests by Geographic Region - US, Europe,
and Rest of World Independently Analyzed with Annual Revenues in US$ Million
for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 3: World Long-term Projections for Automated and Rapid
Microbiological Tests by Geographic Region - US, Europe, and Rest of World
Independently Analyzed with Annual Revenues in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart)
- Table 4: World 10-Year Perspective for Automated and Rapid Microbiological
Tests by Geographic Region - Percentage Breakdown of Revenues for US, Europe,
and Rest of World for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart)
- Table 5: World Recent Past, Current & Future Market Analysis for
Automated and Rapid Microbiological Tests in Clinical Applications by
Geographic Region - US, Europe, and Rest of World Independently Analyzed with
Annual Revenues in US$ Million for Years 2000 through 2010
(includescorresponding Graph/Chart)
- Table 6: World Long-term Projections for Automated and Rapid
Microbiological Tests in Clinical Applications by Geographic Region - US,
Europe, and Rest of World Independently Analyzed with Annual Revenues in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 7: World Recent Past, Current & Future Market Analysis for
Automated and Rapid Microbiological Tests in Clinical Applications by
Equipment Used - Automated Identification & Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis Systems,Streptococcal
Infection Rapid Tests, GC/Chlamydia RapidTests and Other Automated & Rapid
Microbiological Tests Independently Analyzed with Annual Revenues in US$
Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 8: World Long-term Projections for Automated and Rapid
Microbiological Tests in Clinical Applications by Equipment Used - Automated
Identification & Susceptibility Systems, Automated Blood Culture Systems,
Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests,
GC/Chlamydia RapidTests and Other Automated & Rapid Microbiological Tests
IndependentlyAnalyzed with Annual Revenues in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart)
- Table 9: World 10-Year Perspective for Automated and Rapid Microbiological
Tests in Clinical Applicationsby Geographic Region - Percentage Breakdown of
Revenues for US, Europe, and Rest of World forYears 2003, 2008 & 2012
(includes corresponding Graph/Chart)
- Table 10: World 10-Year Perspective for Automated and Rapid
Microbiological Tests in Clinical Applications by Equipment Used - Percentage
Breakdown of Revenues for Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia RapidTests and Other
Automated & Rapid Microbiological Tests for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart)
- Table 11: World Recent Past, Current & Future Market Analysis for
Automated Identification & Susceptibility Systems in Clinical Applications
by Geographic Region - US, Europe, and Rest of World Independently Analyzed
with Annual Revenues in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart)
- Table 12: World Long-term Projections for Automated and Rapid
Microbiological Tests in Clinical Applications by Equipment Used - Automated
Identification & Susceptibility Systems, Automated Blood Culture Systems,
Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests,
GC/Chlamydia RapidTests and Other Automated & Rapid Microbiological Tests
IndependentlyAnalyzed with Annual Revenues in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart)
- Table 13: World 10-Year Perspective for Automated Identification &
Susceptibility Systems in Clinical Applications by Geographic Region -
Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 14: World Recent Past, Current & Future Market Analysis for
Automated Blood Culture Systems in Clinical Applications by Geographic Region
- US, Europe, and Rest of World Independently Analyzed with Annual Revenues in
US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 15: World Long-term Projections for Automated Blood Culture Systems
in Clinical Applications by Geographic Region - US, Europe, and Rest of World
Independently Analyzed with Annual Revenues in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart)
- Table 16: World 10-Year Perspective for Automated Blood Culture Systems in
Clinical Applications by Geographic Region - Percentage Breakdown of Revenues
for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart)
- Table 17: World Recent Past, Current & Future Market Analysis for
Automated Tuberculosis Systems in Clinical Applications by Geographic Region -
US, Europe, and Rest of World Independently Analyzed with Annual Revenues in
US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 18: World Long-term Projections for Automated Tuberculosis Systems
in Clinical Applications by Geographic Region - US, Europe, and Rest of World
Independently Analyzed with Annual Revenues in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart)
- Table 19: World 10-Year Perspective for Automated Tuberculosis Systems in
Clinical Applications by Geographic Region - Percentage Breakdown of Revenues
for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart)
- Table 20: World Recent Past, Current & Future Market Analysis for
Streptococcal Infection Rapid Tests in Clinical Applications by Geographic
Region - US, Europe, and Rest of World Independently Analyzed with Annual
Revenues in US$ Million for Years 2000 through 2010 (includes corresponding
Graph/Chart)
- Table 21: World Long-term Projections for Streptococcal Infection Rapid
Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of
World Independently Analyzed with Annual Revenues in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart)
- Table 22: World 10-Year Perspective for Streptococcal Infection Rapid
Tests in Clinical Applications by Geographic Region - Percentage Breakdown of
Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart)
- Table 23: World Recent Past, Current & Future Market Analysis for
GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US,
Europe, and Rest of World Independently Analyzed with Annual Revenues in US$
Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 24: World Long-term Projections for GC/Chlamydia RapidTests (*) in
Clinical Applications by Geographic Region - US, Europe, and Rest of World
Independently Analyzed with Annual Revenues in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart)
- Table 25: World 10-Year Perspective for GC/Chlamydia Rapid Tests in
Clinical Applications by Geographic Region - Percentage Breakdown of Revenues
for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart)
- Table 26: World Recent Past, Current & Future Market Analysis for
Other Automated & Rapid Microbiological Tests in Clinical Applications by
Geographic Region - US, Europe, and Rest of World Independently Analyzed with
Annual Revenues in US$ Million for Years 2000 through 2010(includes
corresponding Graph/Chart)
- Table 27: World Long-term Projections for Other Automated & Rapid
Microbiological Tests in Clinical Applications by Geographic Region - US,
Europe, and Rest of World Independently Analyzed with Annual Revenues in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 28: World 10-Year Perspective for Other Automated & Rapid
Microbiological Tests in Clinical Applications by Geographic Region -
Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 29: World Recent Past, Current & Future Market Analysis for
Automated and Rapid Microbiological Tests in Non-Clinical Applications by
Geographic Region - US,Europe, and Rest of World Independently Analyzed with
Annual Revenues in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart)
- Table 30: World Long-term Projections for Automated and Rapid
Microbiological Tests in Non-Clinical Applications by Geographic Region - US,
Europe, and Rest of World Independently Analyzed with Annual Revenues in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 31: World 10-Year Perspective for Automated and Rapid
Microbiological Tests in Non-Clinical Applications by Geographic Region -
Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart)
III. MARKET
1. The United States
- A. Market Analysis
- A Current & Future Analysis...
- Rapid Microbiology Tests - A Competitive Profile
- Consolidation in the Automated and Rapid Microbiological Tests Market
- Bioterrorism Tests - Gaining Prominence
- Tracking Trends Across Product Segments
- STD Rapid Tests
- Market Share Trends of Leading Players:
- Table 32: Leading Players in the US Market for GC/Chlamydia Rapid Tests
(2004 & 2005) - Percentage Breakdown of Value Sales by Company for
Gen-Probe, Abbott, Becton Dickinson and Roche (includes corresponding
Graph/Chart)
- Table 33: Leading Players in the US Market for Chlamydia Rapid Tests
(2004 & 2005) - Percentage Breakdown of Value Sales by Company for
Thermo Electron, Wampole / Inverness Medical Innovations, and Quidel
(includes corresponding Graph/Chart)
- Table 34: Leading Players in the US Market for Syphilis Rapid Tests
(2004 & 2005) - Percentage Breakdown of Value Sales by Company for
Becton Dickinson, Wampole/Inverness Medical Innovations, and Others
(includes corresponding Graph/Chart)
- Leading Players in HIV Rapid Testing Market
- Gastrointestinal Rapid Tests
- Market Share Trends of Leading Players
- Table 35: Leading Players in the US Market for C. Difficile Rapid Tests
(2004 & 2005) -Percentage Breakdown of Value Sales by Company for
Wampole/Inverness Medical Innovations, Meridian Biosciences, BioSite, Becton
Dickinson, Thermo Electron, and Others (includes corresponding Graph/Chart)
- Table 36: Leading Players in the US Market for Cryptosporidium Rapid
Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for
Remel, Meridian Biosciences, and Becton Dickinson (includes
correspondingGraph/Chart)
- Table 37: Leading Players in the US Market for Rotavirus Rapid Tests
(2004 & 2005) - Percentage Breakdown of Value Sales by Company for
Meridian Biosciences, FisherScientific, and Others (includes corresponding
Graph/Chart)
- Table 38: Leading Players in the US Market for Giardia Rapid Tests (2004
& 2005) - Percentage Breakdown of Value Sales by Company for Remel,
Meridian Biosciences, and Becton Dickinson (includes corresponding
Graph/Chart)
- Respiratory Rapid Tests
- Competition:
- Table 39: Leading Players in the US Market for Influenza Rapid Tests
(2004 & 2005) - Percentage Breakdown of Value Sales by Company for
Quidel, Becton Dickinson, Thermo Electron, Binax and Others (includes
corresponding Graph/Chart)
- Table 40: Leading Players in the US Market for RSV Rapid Tests (2004
& 2005) - Percentage Breakdown of Value Sales by Company for Becton
Dickinson, Binax, Thermo Electron and Others (includes corresponding
Graph/Chart)
- Table 41: Leading Players in the US Market for Tuberculosis Rapid Tests
(2004 & 2005) - Percentage Breakdown of Value Sales by Company for
Gen-Probe, and Becton Dickinson
- Table 42: Leading Players in the US Market for M. Pneumoniae Rapid Tests
(2004 & 2005) - Percentage Breakdown of Value Sales by Company for
Meridian Biosciences, and Remel, Inc.
- Table 43: Leading Players in the US Market for Mononucleosis Rapid Tests
(2004 & 2005) - Percentage Breakdown of Value Sales by Company for
Wampole, Remel, Quidel, Thermo Electronand Others (includes corresponding
Graph/Chart)
- Streptococcus Infection Rapid Tests
- Table 44: Leading Players in the US Market for Streptococcus A Rapid
Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for
Quidel, Thermo Electron, Becton Dickinson, Genzyme and Others (includes
corresponding Graph/Chart)
- Average Prices
- Table 45: Average Costs for Rapid Tests in the US (includes
corresponding Graph/Chart)
- A Peek into the Testing Practices of the US Food Industry
- Table 46: Microbiology Tests in the US Food Industry by Sector: 2001
(includes corresponding Graph/Chart)
- Product Innovations/Introductions
- Strategic Corporate Developments
- Focus on Key Players
- Abbott Laboratories
- Abbott Diagnostics
- Arlington Scientific, Inc.
- Becton Dickinson And Company
- bioMerieux, Inc.
- Bio-Rad Laboratories
- Gen-Probe Incorporated
- Genzyme Diagnostics
- Inverness Medical Innovations, Inc
- Meridian Biosciences, Inc.
- Orasure Technologies, Inc.
- Quidel Corporation
- Remel Inc.
- Siemens Healthcare Diagnostics
- B. Market Analytics
- Table 47: US Recent Past, Current & Future Market Analysis for
Automated & Rapid Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identification & Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart)
- Table 48: US Long-term Projections for Automated & Rapid
Microbiological Tests by End-Use Segment - Clinical Applications (Automated
Identification & Susceptibility Systems, Automated Blood Culture
Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid
Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid
Microbiological Tests) and Non- Clinical Applications Independently Analyzed
with Annual Revenues in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 49: US 10-Year Perspective for Automated & Rapid
Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues
for Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, C/Chlamydia Rapid Tests, and Other
Automated & Rapid MicrobiologicalTests) and Non-Clinical Applications
for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 50: US Recent Past, Current & Future Market Analysis for Rapid
Microbiological Tests by End-Use Segment - Clinical Applications
(Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B},
STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests
{RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and
Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia,
Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$Million for Years 2000
through 2010 (includes corresponding Graph/Chart)
- Table 51: US Long-term Projections for Rapid Microbiological Tests by
End-Use Segment - Clinical Applications (Streptococcus Infection Rapid Tests
{Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV,
and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis,
Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid
Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori})
and Non-Clinical Applications IndependentlyAnalyzed with Annual Revenues in
US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 52: US 10-Year Perspective for Rapid Microbiological Tests by
End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications
(Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B},
STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests
{RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and
Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia,
Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications
for2003, 2008 & 2012 (includes corresponding Graph/Chart)
2. Europe
- A. Market Analysis
- A Current & Future Analysis
- European Market Primer
- What Drives the Requirement Patterns of End-Users?
- Competitive Profile ...
- Table 53: Leading Players in European Market for Automated & Rapid
Microbiological Tests (2000) - Percentage Breakdown of Value Sales by
Company for bioMerieux, Becton Dickinson, Organon Teknika, Merlin, Abbott,
Dade, Unipath, and Others(includes corresponding Graph/Chart)
- Trends & Issues
- Proliferation of Automated, and Rapid Tests in Europe...
- European Automated Market
- Probe Tests: "A Crack in the Future of Rapid Tests"
- Trends Across Product Segments
- GC/Chlamydia Rapid Tests
- Streptococcal Infection (Strep A) Rapid Tests
- Automated Tuberculosis Systems Market
- Historic Competitive Profile
- Table 54: Leading Players in European Market for Chlamydia Rapid Tests
(2000) - Percentage Breakdown of Value Sales by Company for Abbott, Oxoid,
Unipath, Quidel, and Others (includes corresponding Graph/Chart)
- Table 55: Leading Players in European Market for Streptococcal Infection
(Strep A) Rapid Tests (2000) - Percentage Breakdown of Value Sales by
Company for Abbott, Unipath, Quidel, Orion Diagnostics, Oxoid, and Becton
Dickinson (includes corresponding Graph/Chart)
- Table 56: Leading Players in European Market for Automated Blood Culture
Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton
Dickinson, Organon Teknika, and bioMerieux (includes corresponding
Graph/Chart)
- Product Innovations/Introductions
- B. Market Analytics
- Table 57: European Recent Past, Current & Future Market Analysis for
Automated & Rapid Microbiological Tests by Geographic Region - France,
Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe
Independently Analyzed with Annual Revenuesin US$ Million for Years 2000
through 2010(includes corresponding Graph/Chart)
- Table 58: European Long-term Projections for Automated &Rapid
Microbiological Tests by Geographic Region - France, Germany, The United
Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed
withAnnual Revenues in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 59: European Recent Past, Current & Future Market Analysis for
Automated & Rapid Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identification & Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart)
- Table 60: European Recent Past, Current & Future Market Analysis for
Automated & Rapid Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identification & Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests,and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart)
- Table 61: European 10-Year Perspective for Automated & Rapid
Microbiological Tests by Geographic Region - Percentage Breakdown of
Revenues for France, Germany, The United Kingdom, Italy, Spain, Russia,
& Rest of Europe for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart)
- Table 62: European 10-Year Perspective for Automated & Rapid
Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues
for Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal InfectionRapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications
for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
2a. France
- A. Market Analysis
- A Current & Future Analysis
- Leading Players in Select Segments -Historic Data
- Table 63: Leading Players in French Market for Automated & Rapid
Microbiological Tests (2000) - Percentage Breakdown of Value Sales by
Company for bioMerieux, Becton Dickinson, Merlin, Organon Teknika, Dade,
Pasteur Sanofi Diagnostic, Oxoid and Abbott (includes corresponding
Graph/Chart)
- Chlamydia Rapid Tests
- Table 64: Leading Players in French Market for Chlamydia Rapid Tests
(2000) - Percentage Breakdown of Value Salesby Company for Oxoid and Others
- Automated Tuberculosis Systems
- Table 65: Leading Players in French Market for Automated Tuberculosis
Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton
Dickinson and Others
- Automated Blood Culture Systems
- Table 66: Leading Players in French Market for Automated Blood Culture
Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton
Dickinson, Organon Teknika, bioMerieux, and Pasteur Sanofi Diagnostic
(includes corresponding Graph/Chart)
- Automated Identification and Susceptibility Systems
- Table 67: Leading Players in French Market for Automated Identification
and Susceptibility Systems (2000) - Percentage Breakdown of Value Sales by
Company for bioMerieux, Merlin, Dade, and Becton Dickinson (includes
corresponding Graph/Chart)
- bioMerieux: A Key Player
- Product Innovations/Introductions
- Strategic Corporate Developments
- B. Market Analytics
- Table 68: French Recent Past, Current & Future Market Analysis for
Automated & Rapid Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identification & Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart)
- Table 69: French Long-term Projections for Automated & Rapid
Microbiological Tests by End-Use Segment - Clinical Applications (Automated
Identification & Susceptibility Systems, Automated Blood Culture
Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid
Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid
Microbiological Tests) and Non- Clinical Applications Independently Analyzed
with Annual Revenues in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 70: French 10-Year Perspective for Automated & Rapid
Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues
for Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications
for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
2b. Germany
- A. Market Analysis
- A Current & Future Analysis
- Competitive Structure...
- Leading Players in Select Segments - Historic Data
- Table 71: Leading Players in German Market for Automated & Rapid
Microbiological Tests (2000) - Percentage Breakdown of Value Sales by
Company for bioMerieux, Organon Teknika, Becton Dickinson,Merlin, Abbott,
Unipath, and Others (includes corresponding Graph/Chart)
- Streptococcal Infection Rapid Tests
- Table 72: Leading Players in German Market for Streptococcal Infection
Rapid Tests (2000) Percentage Breakdown of Value Sales by Company for
Abbott, Unipath and Quidel (includes corresponding Graph/Chart)
- Automated Tuberculosis System
- Table 73: Leading Players in German Market for Automated Tuberculosis
Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton
Dickinsonand Others
- Automated Blood Culture Systems
- Table 74: Leading Players in German Market for Automated Blood Culture
Systems (2000) - Percentage Breakdown of Value Sales by Company for
bioMerieux, Becton Dickinson, and Organon Teknika (includes corresponding
Graph/Chart)
- Chlamydia Rapid Tests
- Table 75: Leading Players in German Market for Chlamydia Rapid Tests
(2000) - Percentage Breakdown of Value Sales by Company for Abbott, Unipath,
Quidel, Orgenics and International Microbio (includes corresponding
Graph/Chart)
- Automated Identification and Susceptibility Systems
- Table 76: Leading Players in German Market for Automated Identification
and Susceptibility Systems (2000) - Percentage Breakdown of Value Sales by
Company for bioMerieux, Merlin and Dade (includes corresponding Graph/Chart)
- Merlin Diagnostica GmbH - A Key Player
- B. Market Analytics
- Table 77: German Recent Past, Current & Future Market Analysis for
Automated & Rapid Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identification & Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million for Years 2000
through 2010 (includescorresponding Graph/Chart)
- Table 78: German Long-term Projections for Automated & Rapid
Microbiological Tests by End-Use Segment - Clinical Applications (Automated
Identification & Susceptibility Systems, Automated Blood Culture
Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid
Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid
Microbiological Tests) and Non-Clinical Applications Independently Analyzed
with Annual Revenues in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 79: German 10-Year Perspective for Automated & Rapid
Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues
for Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection RapidTests, GC/Chlamydia Rapid Tests, and
OtherAutomated & Rapid Microbiological Tests) and Non-Clinical
Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
2c. The United Kingdom
- A. Market Analysis
- A Current & Future Analysis...
- Increasing Incidence of MRSA Spur Growth in Rapid Diagnostics
- Leading Players in Select Segments - Historic Data
- Table 80: Leading Players in the UK Market for Automated & Rapid
Microbiological Tests (2000) - Percentage Breakdown of Value Sales by
Company for bioMerieux, Becton Dickinson, Organon Teknika, Unipath, Abbott,
and Others (includes corresponding Graph/Chart)
- Chlamydia Rapid Tests
- Table 81: Leading Players in the UK Market for Chlamydia Rapid Tests
(2000)) - Percentage Breakdown of Value Sales by Company for Abbott,
Unipath, Quidel, Orgenics and International Microbio (includes corresponding
Graph/Chart)
- Automated Tuberculosis System
- Table 82: Leading Players in the UK Market for Automated Tuberculosis
Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton
Dickinson, and Others
- Automated Identification and Susceptibility Systems
- Table 83: Leading Players in the UK Marketfor Automated Identification
and Susceptibility Systems (2000 & 2004) - Percentage Breakdown of Value
Sales by Company for bioMerieux, and Becton Dickinson
- Streptococcal Infection Rapid Tests
- Table 84: Leading Players in the UK Market for Streptococcal Infection
Rapid Tests (2000) - Percentage Breakdown of Value Sales by Company for
Unipath and Abbott
- Automated Blood Culture Systems
- Table 85: Leading Players in the UK Market for Automated Blood Culture
Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton
Dickinson, Organon Teknika, and bioMerieux (includes corresponding
Graph/Chart)
- Product Innovation/Introduction
- Strategic Corporate Developments
- Focus on Select Players
- Celsis International Plc
- Oxoid Limited
- B. Market Analytics
- Table 86: UK Recent Past, Current & Future Market Analysis for
Automated & Rapid Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identification & Susceptibility Systems,
Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart)
- Table 87: UK Long-term Projections for Automated & Rapid
Microbiological Tests by End-Use Segment - Clinical Applications (Automated
Identification & Susceptibility Systems, Automated Blood Culture
Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid
Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid
Microbiological Tests) and Non-Clinical Applications Independently Analyzed
with Annual Revenues in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 88: UK 10-Year Perspective for Automated & Rapid
Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues
for Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests,GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-ClinicalApplications
for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
2d. Italy
- A. Market Analysis
- A Current & Future Analysis...
- Leading Players in Select Segments-- Historic Data
- Table 89: Leading Players in Italian Market for Automated & Rapid
Microbiological Tests (2000) - Percentage Breakdown of Value Sales by
Company for Becton Dickinson, bioMerieux, OrganonTeknika, Dade, Abbott,
Unipath, and Quidel (includes corresponding Graph/Chart)
- Streptococcal Infection Rapid Tests
- Table 90: Leading Players in Italian Market for Streptococcal Infection
Rapid Tests (2000) - Percentage Breakdown of Value Sales by Company for
Abbott, Unipath, Becton Dickinson and Quidel (includes corresponding
Graph/Chart)
- Automated Tuberculosis System
- Table 91: Leading Players in Italian Market for Automated Tuberculosis
Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton
Dickinson, and Others
- Chlamydia Rapid Tests
- Table 92: Leading Players in Italian Market for Chlamydia Rapid Tests
(2000) - Percentage Breakdownof Value Sales by Company for Unipath, Abbott,
and Biolife (includes corresponding Graph/Chart)
- B. Market Analytics
- Table 93: Italian Recent Past, Current & Future Market Analysis for
Automated & Rapid MicrobiologicalTests by End-Use Segment - Clinical
Applications (Automated Identification & Susceptibility Systems,
Automated Blood Culture Systems, AutomatedTuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-ClinicalApplications
Independently Analyzed with AnnualRevenues in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart)
- Table 94: Italian Long-term Projections for Automated & Rapid
Microbiological Tests by End-Use Segment - Clinical Applications (Automated
Identification & Susceptibility Systems, Automated Blood Culture
Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid
Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid
Microbiological Tests) and Non-Clinical Applications Independently Analyzed
with Annual Revenues in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 95: Italian 10-Year Perspective for Automated & Rapid
Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues
for Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems,Automated Tuberculosis Systems,
StreptococcalInfection Rapid Tests, GC/Chlamydia Rapid Tests,and Other
Automated & Rapid Microbiological Tests)and Non-Clinical Applications
for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
2e. Spain
- A. Market Analysis
- A Current & Future Analysis...
- Market Share Trends of Leading Players- Historic Data
- Table 96: Leading Players in Spanish Market for Automated Tuberculosis
Systems (2000) - Percentage Breakdown of Value Sales by Company for
bioMerieux, Organon Teknika, and Becton Dickinson (includes corresponding
Graph/Chart)
- B. Market Analytics
- Table 97: Spanish Recent Past, Current & FutureMarket Analysis for
Automated & Rapid Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identification & Susceptibility Systems,
Automated Blood Culture Systems, AutomatedTuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-ClinicalApplications
Independently Analyzed with Annual Revenues in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart)
- Table 98: Spanish Long-term Projections for Automated & Rapid
Microbiological Tests by End-Use Segment - Clinical Applications (Automated
Identification & Susceptibility Systems, Automated Blood Culture
Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid
Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid
Microbiological Tests) and Non-Clinical Applications Independently Analyzed
with Annual Revenues in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 99: Spanish 10-Year Perspective for Automated & Rapid
Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues
for Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal InfectionRapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications
for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
2f. Russia
- Market Analysis
- A Current & Future Analysis...
- Table 100: Russian Recent Past, Current & Future Market Analysis for
Automated & Rapid Microbiological Tests by End-Use Segment - Clinical
Applications (Automated Identification & Susceptibility Systems, Automated
Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection
Rapid Tests, C/Chlamydia Rapid Tests, and Other Automated & Rapid
Microbiological Tests) and Non-Clinical Applications Independently Analyzed
with Annual Revenues in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart)
- Table 101: Russian Long-term Projections for Automated & Rapid
Microbiological Tests by End-Use Segment - Clinical Applications (Automated
Identification & Susceptibility Systems, Automated Blood Culture Systems,
Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests,
GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological
Tests) and Non-Clinical Applications Independently Analyzed with Annual
Revenues in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart)
- Table 102: Russian 10-Year Perspective for Automated & Rapid
Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues
for Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications for
2003, 2008 & 2012 (includes corresponding Graph/Chart)
2g. Rest of Europe
- A. Market Analysis
- A Current & Future Analysis...
- Leading Players in Select Segments- Historic Data
- Streptococcal Infection Rapid Tests
- Table 103: Leading Players in Streptococcal Infection Rapid Tests Market
in Rest of Europe (2000) - Percentage Breakdown of Value Sales by Company
for Abbott, and Oxoid
- Automated Identification and Susceptibility Systems
- Table 104: Leading Players in Automated Identificationand Susceptibility
Systems Market in Rest of Europe(2000) - Percentage Breakdown of Value Sales
by Company for bioMerieux, and Becton Dickinson
- Product Innovations/Introductions
- Strategic Corporate Developments
- Focus on Select Players
- Coris BioConcept (Belgium)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Orion Diagnostica Oy (Finland)
- B. Market Analytics
- Table 105: Rest of Europe Recent Past, Current & Future Market
Analysis for Automated & Rapid Microbiological Tests by End-Use Segment
- Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart)
- Table 106: Rest of Europe Long-term Projections for Automated &
Rapid Microbiological Tests by End-Use Segment - Clinical Applications
(Automated Identification & Susceptibility Systems, Automated Blood
Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection
Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid
Microbiological Tests) and Non-Clinical Applications Independently Analyzed
with Annual Revenues in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 107: Rest of Europe 10-Year Perspective for Automated & Rapid
Microbiological Tests by Product Segment - Percentage Breakdown of Revenues
for Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated & Rapid Microbiological Tests) and Non-Clinical Applications
for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
3. Rest of World
- A. Market Analysis
- A Current & Future Analysis...
- Latin American Market
- Asia-Pacific - The Next Epicenter for the AIDS Epidemic...
- Product Innovations/Introductions
- Strategic Corporate Developments
- Focus on Select Players
- Cellabs Pty Ltd (Australia)
- MedMira Inc. (Canada)
- B. Market Analytics
- Table 108: Rest of World Recent Past, Current & Future Market
Analysis for Automated & Rapid Microbiological Tests by End-Use Segment
- Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated &Rapid Microbiological Tests) and Non-Clinical Applications
Independently Analyzed with Annual Revenues in US$ Million for Years 2000
through2010 (includes corresponding Graph/Chart)
- Table 109: Rest of World long-term Projections for Automated & Rapid
Microbiological Tests by End-Use Segment - Clinical Applications (Automated
Identification & Susceptibility Systems, Automated Blood Culture
Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid
Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid
Microbiological Tests) and Non- Clinical Applications Independently Analyzed
with Annual Revenues in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 110: Rest of World 10-Year Perspective for Automated & Rapid
Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues
for Clinical Applications (Automated Identification & Susceptibility
Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,
Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other
Automated &Rapid Microbiological Tests) and Non-Clinical Applications
for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
|
